Check for updates

OPEN ACCESS

EDITED BY Joao Luiz Quaglioti Durigan, University of Brasilia, Brazil

REVIEWED BY Klaus Porto Azevedo, University of Brasilia, Brazil Isabella Da Silva Almeida, University of Brasilia, Brazil

*CORRESPONDENCE Fei Li ⊠ 763105199@qq.com

RECEIVED 07 April 2024 ACCEPTED 12 July 2024 PUBLISHED 31 July 2024

CITATION

Li L, Li F, Zhang X, Song Y, Li S and Yao H (2024) The effect of electrical stimulation in critical patients: a meta-analysis of randomized controlled trials. *Front. Neurol.* 15:1403594. doi: 10.3389/fneur.2024.1403594

COPYRIGHT

© 2024 Li, Li, Zhang, Song, Li and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The effect of electrical stimulation in critical patients: a meta-analysis of randomized controlled trials

Lili Li, Fei Li*, Xinyin Zhang, Yuying Song, Shuyan Li and Huiping Yao

Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China

Objectives: While electrical stimulation has been demonstrated to improve medical research council (MRC) scores in critically ill patients, its effectiveness remains a subject of debate. This meta-analysis aimed to discuss recent insights into the effectiveness of electrical stimulation in improving muscle strength and its effects on different clinical outcomes in critically ill adults.

Methods: A comprehensive search of major electronic databases, including PubMed, Cochrane Library, and Embase, was conducted from inception to June 15, 2024, to identify randomized controlled trials (RCTs) that evaluated the effects of electrical stimulation in critically ill patients. The analysis focused on comparing electrical stimulation to standard care, sham interventions, or placebo. Outcomes of interest included MRC scores, duration of mechanical ventilation (MV), mortality rate, and intensive care unit (ICU) and hospital length of stay (LOS).

Results: A total of 23 RCTs, including 1798 patients, met the inclusion criteria. The findings demonstrated a significant benefit of electrical stimulation over usual care in enhancing global muscle strength, as measured by MRC scores (MD = 3.62, 95% CI 0.94 to 6.30, p=0.0008, I² =87%). While subgroup analysis of electrical muscle stimulation (EMS) demonstrated no significant effect on ICU LOS, sensitivity analysis indicated a potential reduction in ICU LOS for both EMS (MD=-11.0, 95% CI -21.12 to -0.88, p=0.03) and electrical stimulation overall (MD=-1.02, 95% CI -1.96 to -0.08, p=0.03) compared to the control group. In addition, sensitivity analysis suggested that both electrical stimulation (MD=-2.38, 95% CI -3.81 to -0.94, p=0.001) and neuromuscular electrical stimulation (NMES) specifically (MD=-2.36, 95% CI -3.85 to -0.88, p=0.002) may contribute to a decrease in hospital LOS. No statistically significant differences were observed in mortality or duration of MV.

Conclusion: Electrical stimulation appears to be an effective intervention for improving MRC scores in critically ill patients. However, further research is warranted to explain the potential effects of electrical stimulation on hospital LOS and ICU LOS.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ #recordDetails.

KEYWORDS

electrical stimulation, ICU, meta-analysis, physical therapy, randomized controlled trial

Introduction

ICU-acquired weakness (ICU-AW), a debilitating condition characterized by muscular weakness arising from a confluence of risk factors in intensive care unit (ICU) stays, is a prevalent concern. Studies indicate that the incidence of ICU-AW in critically ill patients can reach up to 70% (1). This condition has significant implications for patient outcomes, correlating with extended durations of mechanical ventilation (MV), protracted ICU and hospital lengths of stay (LOS), increased hospital mortality rates, and the persistence of debilitating weakness (2, 3). Proactive interventions for ICU patients are considered crucial in reducing the development of ICU-AW (4). Early implementation of active rehabilitation methods has demonstrated effectiveness in enhancing muscle strength and mobility, simultaneously reducing hospital LOS and mortality rates among ICU patients (5, 6). However, the feasibility and extent of early functional training can be limited by the severity of a patient's medical condition and their capacity for active participation. Electrical stimulation presents a non-invasive and safe alternative, particularly valuable for patients in the early stages of their ICU stay, especially those who are unconscious or necessitate sedation (7). Research suggests that electrical stimulation confers a therapeutic advantage in managing ICU-AW, leading to increased muscle strength, shortened MV durations, and reduced ICU LOS (8, 9); whereas, a subset of studies has reported no significant improvements in muscle strength attributable to electrical stimulation in ICU-AW (2, 10, 11). Therefore, despite the widespread clinical adoption of electrical stimulation, its effectiveness for ICU patients continues to be a subject of debate.

A prior systematic review (2), which considered studies published through 2020, comprised six randomized controlled trials (RCTs) identified through a search concluded in November 2018. Since then, new analyses in this area have been conducted. For instance, Zayed et al. (2) studied adult patients admitted to the ICU for medical or surgical reasons, irrespective of their need for MV, and found that integrating electrical stimulation into standard care did not yield significant differences in muscle strength, ICU mortality, MV duration, or ICU LOS compared to standard care alone for critically ill patients; whereas, Baron et al. (12) and Chen et al. (3) demonstrated that electrical stimulation could potentially shorten ICU LOS.

The purpose of this review was to present recent findings on the effectiveness of electrical stimulation for enhancing muscle strength and its impact on various clinical outcomes in critically ill adults.

Methods

The research adhered rigorously to the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements (13). Furthermore, it was officially registered with PROSPERO on September 12, 2022, and was assigned the registration number CRD42022350794. This study protocol was registered after the first literature search.

Search strategy

A systematic search of literature and electronic databases such as PubMed, Cochrane Central Register of Controlled Trials, and Embase was conducted from their inception until June 15, 2024. The initial literature search was conducted on July 7, 2022. The strategy to develop search terms involved a blend of subject terms and freely used words. This includes terms like "electric stimulation therapy," "intensive care units," "critical illness," and "ICU." A detailed combination of free words and subject terms was utilized for retrieving literature, and the specifics of this search strategy can be found in Appendix 1.

Inclusion and exclusion criteria

The inclusion criteria were: (1) Study type: RCT, not limited to allocation concealment and blinding method; (2) Study population: ICU mechanically ventilated patients aged \geq 18 years; (3) Interventions: Research electrical stimulation or combined conventional therapy in the observation group; (4) Comparisons: Usual care measures or comfort treatment in the control group; (5) Outcome: The primary outcome was the Medical Research Council (MRC) scale score, while the secondary outcomes were the duration of MV, mortality, ICU LOS, and hospital LOS; and (6) Language: Only articles published in English.

The exclusion criteria were: (1) conference abstracts; (2) case studies or Meta-analyses; and (3) studies where data were missing or could not be converted.

Literature screening and data extraction

A pair of reviewers separately perused through the scholarly records using EndNote 20.0, concurrently validated the compiled data, and sought judgment from a third-party researcher during disparities. The process of screening the literature implied a thorough examination of the title, abstract, and the complete text. In situations where critical information, necessary for the study was missing, the original authors of the papers were reached out to, either via email or call. Excel was employed for data organization included several components such as the authors' names, year of publication, Acute Physiology and Chronic Health Evaluation II (APACHE II), sample size, age demographics, gender, intervention strategies, and final outcomes.

Literature quality evaluation

Two reviewers conducted independent assessments of the risk of bias in the studies included in the review using the risk of bias assessment tool for RCTs as outlined in Cochrane Workbook 6.4, 2023 (14). In cases where there was a difference in their assessments, a third investigator was involved in discussions or arbitration to reach a consensus. The evaluation encompassed various aspects, including random sequence generation, allocation concealment, blinding of participants and investigators, blinding of outcome assessors, completeness of outcome data, selective reporting and other potential sources of bias. Each of these aspects was rated as "low risk of bias," "unclear," or "high risk of bias," with a determination of "high risk of bias" made for each specific item where applicable.

Statistical analysis

We derived risk ratios (RRs) for categorical data and evaluated mean differences (MDs) for ongoing data, pairing them with their respective 95% confidence intervals (CIs) under a random-effect model. We gauged heterogeneity across studies using metric like $\tau 2$, χ^2 (Cochrane Q), and I² statistics. According to the Cochrane handbook, the I² will be considered non-important (<30%), moderate (30–60%), and substantial (>60%) (14). Our findings were represented visually through forest plots. To evaluate the effect of individual studies on the overall results, we employed a sequential study removal method, iteratively excluding each study and recalculating the pooled effect size. For gauging publication bias, we used a funnel plot for Meta-analysis and employed Egger's method for quantification, provided more than ten studies incorporated the results. We also executed subgroup evaluations focusing on the various electrical stimulation forms. Our statistical reviews were performed using the RevMan 5.4 software, establishing a statistical significance benchmark at a value below 0.05.

Results

Summary of included studies

We identified a total of 7,768 studies related to our research. After checking for duplicates, screening titles, and browsing abstracts, we eliminated 7,745 studies that did not meet our inclusion criteria. The search process and study selection are illustrated in Figure 1. In the end, 23 randomized controlled trials (RCTs) (3, 12, 15–35) were included, covering a total of 1798 patients, of which 48.5% were females, conducted in 10 different countries and published between the years 2009 and 2023. The individual studies included a sample size range between 20 to 312 critical patients, and nearly 30.4% of the studies involved patients whose mean or median age was over 60 years.

The interventions in these trials were neuromuscular electrical stimulation (NMES) in 16 studies, electrical muscle stimulation (EMS) in five, and functional electrical stimulation (FES) in two. Notably, Abu-Khaber et al. (15) compared the effects of EMS with a placebo, Kho et al. (16) and Fischer et al. (17) compared it with a sham intervention, and Campos et al. (18) compared it with early mobilization. Table 1 provides additional details of the research and the clinical characteristics of the patients. This study employed a leave-one-out approach, removing the included studies one by one to observe changes in the results after the exclusion of specific studies, in order to examine the impact of any single study on the overall effect estimate. The results are shown in Table 2.

We appraised the included studies against seven domains for the risk of bias, which we categorized as 'low', 'high', or 'unclear'. The results from these individual studies are summarized in Figure 2. We found that the method of randomized controlled allocation was flawed in three studies and was not expressly delineated in two studies. In six studies, the participants and personnel were not blinded, and in two studies, the outcome measures were not blinded.

Outcome results

Mortality and duration of MV

The effect of electrical stimulation on mortality was reported in fifteen studies, including 1,278 patients. The results showed no difference in mortality in the electrical stimulation group compared to the control group (RR=1.05,95% CI 0.86 to 1.28, p=0.62) (Figure 3) with acceptable heterogeneity (I² = 0%). Seventeen studies reported the effect of electrical stimulation on the duration of MV. The comparison between the electrical stimulation group and the control group showed no significant difference in the MV time (MD = -2.35, 95% CI -6.52 to 1.82, p=0.27, I² = 98%) (Figure 4). The subgroup and sensitivity analysis for EMS, FES, and NMES outcomes showed no differences in the mortality and the duration of MV.

ICU LOS

Sixteen studies reported the effect of electrical stimulation on ICU LOS. The results showed that there was no statistical difference in the electrical stimulation group compared with the control group $(MD = -2.41, 95\% CI - 6.23 to 1.42, p = 0.22, I^2 = 99\%)$ (Figure 5). The subgroup analysis of EMS showed no differences in ICU LOS, but the sensitivity analysis reported the EMS could decrease the ICU LOS after excluding the study by Nakamura et al. (27) (MD = -11.0, 95% CI -21.12 to -0.88, p = 0.03). Nakamura et al. (27) primarily focused on patients with low APACHE II scores, and the ICU LOS was shorter than in other ICUs, which may be the main source of heterogeneity. The sensitivity analysis showed that the electrical stimulation could decrease the ICU LOS compared with the control group after excluding the study by Mahran et al. (25) (MD = -1.02, 95% CI -1.96to -0.08, p=0.03) (Table 2). Mahran et al. (25) focused on adult patients who were admitted to the ICU and required MV on the first day of admission, and aimed to evaluate the short-term outcomes of electrical stimulation in critically ill patients.

Hospital LOS

A total of nine studies, encompassing 451 patients, explored the impact of electrical stimulation. Statistical difference was not observed in hospital LOS when compared to the control group (MD = -1.45, 95% CI -4.12 to 1.23, p = 0.29, I² = 44%) (Figure 6). The subgroup analysis of EMS showed no differences in hospital LOS, but the sensitivity analysis was conducted and identified the study by Sumin et al. (33) as the primary source of heterogeneity. Excluding this study, the results indicated the electrical stimulation (MD = -2.38, 95% CI -3.81 to -0.94, p = 0.001) and the subgroup of NMES (MD = -2.36, 95% CI -3.85 to -0.88, p = 0.002) led to a reduction in hospital LOS in comparison to the control group (Table 2). The research by Sumin et al. (33), which assessed the efficacy of NMES during the initial rehabilitation phase for patients experiencing postoperative complications following cardiovascular surgery, did not blind the assessors of muscle strength, which is presumed to be a significant source of heterogeneity.

MRC scores

Eleven studies, including 989 patients, reported the effect of electrical stimulation on MRC scores. The results showed that the MRC scores were significantly improved in the electrical stimulation group compared with the control group (MD=3.62, 95% CI 0.94 to 6.30, p=0.008, I² = 87%) (Figure 7). The subgroup analysis of NEMS



showed differences on MRC scores (MD = 5.12, 95% CI 1.36 to 8.87, p = 0.008, I² = 89%) (Figure 7).

Publication bias

Studies reporting on hospital LOS were less than ten, so we did not visualize the results using funnel plots. The funnel plots did not reveal obvious asymmetry for analyses on morality, duration of MV, MRC scores and the ICU LOS. Consistently, the Egger test suggested a lack of publication bias for morality (p=0.25), duration of MV (p=0.17), and ICU LOS (p=0.15). Based on this analysis, the studies encompassed provided a broad coverage and produced statistically robust outcomes.

Discussion

The objective of this review was to compile recent research on the effectiveness of electrical stimulation in boosting muscle strength and influencing various clinical outcomes in critically ill adults. We found that electrical stimulation significantly improves MRC scores, and there were no statistically significant differences in any other outcomes. Subgroup analysis suggests that NMES can effectively improve patients' MRC scores. However, sensitivity analyses showed that electrical stimulation could reduce ICU LOS and hospital LOS. In addition, EMS effectively shortened the ICU LOS and NMES decreased the hospital LOS in sensitivity analyses. 05

TABLE 1 Characteristics of included studies.

Study	Country			N	MES group	c				Control gro	oup		Outcome
		APACHE II	Sample size	Age (year)	Female (%)	Intervention (NMES/EMS/ FES)	Treatment in the experimental group	APACHE II	Sample size	Age (year)	Female (%)	Intervention	
Abu-Khaber, 2013 (15)	Egypt	24.5±6.8	40	59.07±5.32	24 (60%)	EMS	Frequency: daily, from the second day after admission Intensity:50 Hz, pulse width of 200 µs	26.1±5.3	40	57.57±6.80	27 (67.5%)	Placebo	Mortality Duration of MV
Baron, 2022 (12)	Brazil	NE	76	62.8±17.4	38 (50.0%)	NMES	Frequency: 25 min, once a day, six times a week Intensity:100 Hz, pulse width of 500 µs	NE	73	63.7±18.2	42 (57.5%)	Usual care	Mortality ICU LOS Duration of MV
Campos, 2022 (18)	Brazil	NE	34	42.5±14.9	10 (30%)	NMES	Frequency: once a day for 60 min, five days a week Intensity:80 Hz, pulse width of 400 µs	NE	40	46.7±17.9	14 (35%)	Early mobilization	Hospital LOS ICU LOS Duration of MV
Cerqueira, 2018 (19)	Brazil	NE	26	41.80 (13.17)	18 (69.2%)	NMES	Frequency: twice a day, (2×60 min) Intensity:50-Hz, pulse width of 400 µs	NE	33	42.21 (14.36)	23 (69.7)	Usual care	ICU LOS MRC
Chen, 2019 (3)	China	20.8±7.4	16	77.7±14.3	8 (50.0%)	EMS	Frequency: two 30-min per day, 5 d/ wk. for 2 wk. Intensity: 50 Hz, pulse width of 400 µs	20.3±6.3	17	73.8±17.8	9 (52.9%)	Usual care	Mortality Duration of MV ICU LOS MRC

10.3389/fneur.2024.1403594

TABLE 1	(Continued)

Study	Country			N	MES group	C				Control gro	oup		Outcome
		APACHE II	Sample size	Age (year)	Female (%)	Intervention (NMES/EMS/ FES)	Treatment in the experimental group	APACHE II	Sample size	Age (year)	Female (%)	Intervention	
Chen A, 2019 (20)	China	19.81±4.42	27	62.40±13.60	14 (51.8%)	NMES	Frequency: 30 min twice daily until the patient was transferred from the ICU Intensity:30 to 40 Hz	19.03±4.23	29	59.83±11.75	17	Usual care	MRC ICU LOS Duration of MV Hospital LOS
Dall' Acqua, 2017 (21)	Brazil	26 (5)	11	56 (13)	4 (36.3%)	NMES	Frequency: 30 min. One minute was added every 2 days of administration. Intensity: 50 Hz, pulse width of 300 µs	29 (7)	14	61 (15)	5 (35.7%)	Usual care	ICU LOS Duration of MV Mortality
Fischer, 2016 (17)	Austria	NE	27	63.3 (15.5)	18 (66.7%)	NMES	Frequency: twice a day (2 × 30 min) Intensity:66 Hz, pulse width of 400 µs	NE	27	69.7 (13.1)	20	Sham	Mortality MRC ICU LOS Duration of MV
Fossat, 2018 (22)	France	NE	158	65 (13)	103 (65%)	EMS	Frequency: 50 min Intensity: a 4-channel electrical simulator	NE	154	66 (15)	98 (64%)	Usual care	MRC Mortality
Gerovasili1, 2009 (23)	Greece	19±3	13	59±23	7 (53.8%)	NMES	Frequency: 55 min, the second to ninth day Intensity: 45 Hz, pulse width of 400 µs	18±6	13	56±19	5	Usual care	Duration of MV
Kho, 2015 (16)	USA	25 (8)	16	54 (16)	9 (56%)	NMES	Frequency: daily, 60 min Intensity: 50 Hz, pulse width of 400 µs	25 (6)	18	56 (18)	8 (50%)	Sham	Duration of MV ICU LOS Hospital LOS Mortality,

(Continued)

TABLE 1 (Continued)

Study	Country			N	MES group)				Control gro	oup		Outcome
		APACHE II	Sample size	Age (year)	Female (%)	Intervention (NMES/EMS/ FES)	Treatment in the experimental group	APACHE II	Sample size	Age (year)	Female (%)	Intervention	
Liu, 2023 (24)	China	20.55 ± 6.40	40	58.13±15.54	15 (37.5%)	NMES	Frequency: daily, sessions for 55 min Intensity:50 Hz, pulse duration 300 ms	19.78±6.44	40	59.08±16.02	17 (42.5%)	Usual care	Duration of MV MRC score ICU LOS Hospital LOS
Mahran, 2023 (25)	Egypt	12.28±4.15	60	31±10	14 (23.3%)	NMES	Frequency: daily, sessions for 55 min Intensity: 46 Hz	15.41±7.30	58	31±10	8 (13.8%)	Usual care	Mortality ICU LOS Duration of MV
McCaughey, 2019 (26)	Australia	NE	10	56.5 (18.50)	3 (30%)	FES	Frequency: 30 min, twice per day, days per week Intensity: 30 Hz, pulse width of 350 µs	NE	10	61.0 (17.25)	5 (50%)	Usual care	Mortality ICU LOS Duration of MV
Nakamura, 2019 (27)	Japan	22.8 (6.2)	21	76.6 (11.0)	14 (66.7%)	EMS	Frequency: once a day, 20 min Intensity: 20 Hz, pulse width of 250 µs	22.9 (3.9)	16	74.6 (13.1)	11 (68.8%)	Usual care	ICU LOS Duration of MV Mortality
Othman, 2023 (28)	Egypt	28.03±4.42	30	40.30±9.252	15 (50.0%)	NMES	Frequency: daily, sessions for 10 min Intensity: 50 Hz, pulse width of 400 µs	40.30±9.252	30	42.43±13.153	16 (53.3%)	Usual care	MRC scores ICU LOS Duration of MV ICU-AW
Patsaki, 2017 (29)	Greece	14 (9)	63	53±15	19 (30%)	NMES	Frequency: daily for 55 min Intensity: 45 Hz, pulse width of 400 µs	17 (9)	65	53±16	26 (40%)	Usual care	MRC Hospital LOS
Routsi, 2010 (30)	Greece	18±4	68	61±19	22 (32.3%)	EMS	Frequency: daily, 55 min Intensity: 45 Hz, pulse width of 400 µs	18±5	72	58±18	23	Usual care	Mortality MRC ICU LOS Duration of MV

(Continued)

Study	Country			Ν	MES group	c				Control gro	oup		Outcome
		APACHE II	Sample size	Age (year)	Female (%)	Intervention (NMES/EMS/ FES)	Treatment in the experimental group	APACHE II	Sample size	Age (year)	Female (%)	Intervention	
Santos, 2020 (31)	Brazil	15.9 (3.2)	11	50.2 (12.8)	7 (66.66%)	NMES	Frequency: twice- daily Intensity: 45 Hz, pulse width of 400 µs	15.3 (3.7)	15	51.8 (12.8)	11 (73.33%)	Usual care	ICU LOS Mortality Duration of MV
Silva, 2019 (32)	Brazil	11 (8–13)	30	30 (27 to 33)	26 (13%)	NMES	Frequency: once a day for 25 min Intensity: 100 Hz, pulse width of 400 µs	11 (9–14)	30	33 (29 to 37)	26 (13%)	Usual care	Duration of MV ICU LOS Hospital LOS Mortality
Sumin, 2020 (33)	Russian	NE	18	61.5 (52.0;71.0)	12 (66.7%)	NMES	Frequency: daily, 90 min each Intensity: 45 Hz	NE	19	64.0 (60.0;68.0)	13 (68.4%)	Usual care	ICU LOS Hospital LOS
Vieira, 2023 (34)	Brazil	16.1±4.6	20	34.7±11.2	4 (20%)	NMES	Frequency: daily, sessions for 55 min Intensity: 50 Hz, pulse width of 400 µs	16.7±4.5	20	36.5±13.5	4 (20%)	Usual care	Mortality ICU LOS Duration of MV Hospital LOS
Waldauf, 2021 (35)	Czech Republic	22.1±5.2	75	59.9±15.1	22 (29.3%)	FES	Frequency: daily, 90 min Intensity: 40 Hz, pulse width of 250 µs	22.2±7.7	75	62.3±15.4	18	Usual care	Mortality MRC

NMES, Neuromuscular electrical stimulation; EMS, electrical muscle stimulation; FES, Functional electrical stimulation; APACHE II, Acute physiology and chronic health evaluation II; MV, Mechanical ventilation; MRC, Medical research council; ICU, Intensive care

unit; LOS, Length of stay. Data are provided as means (standard deviation), means (95% confidence interval) or medians (interquartile range). NE, not estimable.

TABLE 2 Sensitivity analysis (omitting a signal RCT).

Selected study omitted		Hospital LOS (95%CI)	ICU LOS (95%CI)
Nakamura, 2019 (27)	EMS	/	-11.0 (-21.12 to -0.88)
Mahran, 2023 (25)	Total	/	-1.02 (-1.96 to -0.08)
Sumin, 2020 (33)	NMES	-2.36 (-3.85 to -0.88)	/
	Total	-2.38 (-3.81 to -0.94)	/

NMES, neuromuscular electrical stimulation; EMS, electrical muscle stimulation; ICU, intensive care unit; LOS, length of stay. Data are provided as mean differences (95% confidence interval); /, no statistical difference.

Electrical stimulation methods, including NMES, EMS, and FES, utilize electrical currents to stimulate muscles or nerves, while these terms can be often utilized interchangeably, each has its own subtle differentiating uniqueness. NMES aims to restore voluntary movement by activating neurons that have lost their autonomous motor function, triggering skeletal muscle contractions. It also promotes neuromuscular and systemic blood flow, shielding neurons and muscle fibers from the negative effects of tissue hypoxia (36-39). By stimulating the peripheral nervous system, NMES can elicit various responses in the central nervous system, leading to neural adaptations (19-21). EMS, in comparison, focuses on maintaining or improving muscle tone and strength, particularly during periods of reduced physical activity, such as extended bed rest or critical illness (15, 27). It works by applying a series of electrical stimuli directly to skeletal muscles, inducing contractions and aiding in the restoration of muscle strength in critically ill patients. FES, meanwhile, employs carefully designed programs with low-frequency pulsed currents at specific intensities to stimulate and promote the recovery of impaired muscle functions (17). This targeted approach can be applied to individual or multiple muscle groups, with the goal of restoring function to the affected muscles.

Electrical stimulation has been applied to ICU patients as a safe, reliable, and effective way to accelerate their recovery (35). Compared to active training, electrical stimulation does not require patients' participation and can be used in the very early stages of patient admission. Current evidence suggests that electrical stimulation is effective in preventing muscle atrophy in ICU patients, but there is no consistent conclusion on the effects of electrical stimulation on enhancing the motor function and reducing the duration of MV in ICU patients, and further studies are needed. Electrical stimulation aids in the promotion of muscle protein synthesis (40) and enhances muscle microcirculation in various acute conditions (38). As such, it has been adopted in the ICU as a method to counteract or reduce muscle wastage (41). The process involves triggering muscle contractions by sending electrical pulses through surface electrodes. This means there's no need for the patient's active participation, making it especially beneficial for those under continuous IV sedation or in early phases of acute diseases marked by delirium or significant unconsciousness. Recognizing this is crucial since muscle deterioration begins quickly, and the most substantial decline in muscle mass and function is seen within the first two weeks of ICU admission (42).



Risk of bias summary: Low risk of bias: Unclear: High risk of bias.

Previous meta-analyses of electrical stimulation have drawn various conclusions (11). The inclusion criteria for these previous meta-analyses differed from this current study regarding the types of

	interver	ition	Contr	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 NMES							
Baron2022[12]	6	76	4	73	2.6%	1.44 [0.42, 4.90]	
Dall' Acqua2017[21]	3	11	3	14	2.0%	1.27 [0.32, 5.12]	
Fischer2016[17]	1	27	3	27	0.8%	0.33 [0.04, 3.01]	
<ho2015[16]< td=""><td>3</td><td>16</td><td>1</td><td>18</td><td>0.8%</td><td>3.38 [0.39, 29.28]</td><td></td></ho2015[16]<>	3	16	1	18	0.8%	3.38 [0.39, 29.28]	
Mahran2023[25]	23	60	27	58	21.6%	0.82 [0.54, 1.26]	
Nakamura2019[27]	10	21	8	16	8.8%	0.95 [0.49, 1.85]	
Santos2020[31]	3	11	8	15	3.3%	0.51 [0.17, 1.50]	
Silva2019[32]	5	30	3	30	2.2%	1.67 [0.44, 6.36]	
/ieira2023[34]	8	20	7	20	6.0%	1.14 [0.51, 2.55]	
Subtotal (95% CI)		272		271	48.0%	0.93 [0.70, 1.24]	\bullet
Total events	62		64				
Heterogeneity: Tau ² = 0	.00; Chi² =	5.42, d	f = 8 (P =	= 0.71);	l² = 0%		
Test for overall effect: Z	= 0.49 (P	= 0.62)					
1.1.2 EMS							
Abu-Khaber 2013[15]	4	40	6	40	2.7%	0.67 [0.20, 2.18]	
ChenA 2019[20]	3	16	2	17	1.4%	1.59 [0.30, 8.33]	
Fossat 2018[22]	33	158	24	154	17.0%	1.34 [0.83, 2.16]	+
Routsi2010[30]	28	68	22	72	19.1%	1.35 [0.86, 2.11]	+
Subtotal (95% CI)		282		283	40.3%	1.29 [0.95, 1.76]	◆
Total events	68		54				
Heterogeneity: Tau ² = 0	.00; Chi² =	1.32, d	f = 3 (P =	= 0.73);	l² = 0%		
Test for overall effect: Z	= 1.61 (P	= 0.11)					
1.1.3 FES							
AcCaughey2019[26]	2	10	4	10	1.8%	0.50 [0.12, 2.14]	
Waldauf2020[35]	15	75	16	75	9.8%	0.94 [0.50, 1.76]	
Subtotal (95% CI)		85		85	11.6%	0.85 [0.48, 1.51]	
otal events	17		20				
Heterogeneity: Tau ² = 0	.00; Chi² =	0.61, d	f = 1 (P =	= 0.44);	l² = 0%		
Test for overall effect: Z	= 0.56 (P	= 0.58)		,			
Total (95% Cl)		639		639	100.0%	1.05 [0.86, 1.28]	◆
Fotal events	147		138				
Heterogeneity: Tau ² = 0	.00; Chi² =	10.21,	df = 14 (F	⊃ = 0.7	5); l² = 0%		
Test for overall effect: Z	= 0.49 (P	= 0.62)					UUD U.2 1 5 20
Test for subaroup differe	ences: Chi	² = 2.89	. df = 2 (F	> = 0.24	4). I² = 30.8	3%	Favous intervention Favous Control
E 3	- stallta s						
st plot of duration of m	ortality.						

interventions included (NMES, FES, and EMS compared to usual care only). Burke et al. (43) showed in a meta-analysis that, despite some conflicting individual study results, NMES in the ICU was significantly superior in preserving muscle strength, similar to our findings. In congruent with our finding, Lin et al. (44) reported that early implementation of NMES in ICU patients could prevent ICU-AW and improve their quality of life by enhancing their muscle strength and shortening ICU LOS. Furthermore, Zayed et al., in their 2020 study (2), reported that NMES did not reveal substantial variances in overall muscle strength and the length of stay in the hospital when compared to standard care in critically ill patients. This differs from our results, which indicates distinctions in hospital LOS. Cheng et al. (8) showed that NMES in the lower extremities could effectively shorten the duration of MV but had no significant advantages in increasing MRC scores, reducing ICU mortality, and shortening ICU LOS.

Our meta-analysis focused specifically on the effect of electrical stimulation within the ICU and included several recently published studies, and the results highlight a significant decreased in hospital LOS and improved MRC scores. Meanwhile, the subgroup of NMES showed differences in the outcomes. However, the sensitivity analysis demonstrated that EMS could shortened the ICU LOS and NMES decreased the hospital LOS.

Strengths and limitations

The primary strength of this study is its inclusion of numerous RCTs, along with the use of subgroup and sensitivity analyses to minimize biases, thereby ensuring the reliability of the data and the stability of the results. By strictly adhering to the guidelines of the Cochrane Handbook, the research achieves a high degree of standardization and scientific rigor. The findings indicate that electrical stimulation can significantly improve the MRC scores in ICU patients, offering a practical therapeutic foundation for clinical application and potentially benefiting the rehabilitation process of critically ill patients. However, it's important to consider potential limitations and the overall quality of the included studies to fully assess the reliability of these findings. Nevertheless, there were some limitations to this study. The included literature is only published in English, which may lead to publication bias due to an incomplete literature search. In addition, the sample size of individual studies is small, which may affect the analysis results. Furthermore, some studies were not blinded in the implementation of electrical stimulation and measurement results, which may lead to some implementation and measurement bias. Finally, the wide age range of the adult ICU patients on mechanical ventilation included in this study introduces

	Inte	rventio	n Tatal		ontrol	T . 4 . 1	14/-1-1-4	Mean Difference	Mean Difference
Study or Subgroup	Mean	50	lotal	Mean	SD	lotal	weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 NWES	5.0	4.4	75	4.6	2.0	70	6.00/	4 00 10 00 0 001	_
Baron2022[12]	5.8	4.1	75	4.6	3.2	13	6.8%	1.20 [0.02, 2.38]	
Campos2022[18]	10	5.19	34	7.04	7.41	40	0.0%	-2.00 [-4.88, 0.88]	
Cnen2019[3]	5.12	2.01	21	7.24	4.35	29	6.7%	-2.12 [-3.88, -0.36]	
Dall Acqua2017[21]	/	2	11	8	3	14	6.7%	-1.00 [-2.97, 0.97]	
Gerovasili2009[23]	9	2	13	9	3	12	6.7%	0.00 [-2.02, 2.02]	
Kho2015[16]	20	18	16	16	15	18	4.6%	4.00 [-7.22, 15.22]	
Liu2023[24]	109.5	92.59	40	189.5	157	40	0.5%	-80.00 [-136.48, -23.52]	_
Mahran2023[25]	3.3	1.6	60	17.2	1.5	58	6.8%	-13.90 [-14.46, -13.34]	
Othman2023[28]	18.73	4.748	30	20.7	3.932	30	6.7%	-1.97 [-4.18, 0.24]	
Santos2020[31]	9	7	11	14.8	5.4	14	6.2%	-5.80 [-10.81, -0.79]	
Silva2019[32]	14	7.41	30	15.5	7.56	30	6.4%	-1.50 [-5.29, 2.29]	
Vieira2023[34]	11.6	5	20	9.9	5.8	20	6.5%	1.70 [-1.66, 5.06]	
Subtotal (95% CI)			367			378	71.1%	-2.71 [-7.88, 2.46]	
2 1 2 FMS	2 = 1.03	,P = 0.30	0)						
Abu-Khaber 2013[15]	9.01	8 01	40	11 97	8 07	40	6.5%	-2 96 [-6 48 0 56]	_ _
ChenA 2019[20]	21.5	23.55	16	20	22 59	17	3.5%	1 50 [-14 26 17 26]	
Eossat 2018[22]	5.6	20.00	158	20	6 73	154	6.7%	-0.40[-1.82, 1.02]	_ _
Nakamura2019[27]	0.0 Q Q	62	21	85	4 5	16	6.5%	1 40 [-2.05, 4.85]	
Routei2010[30]	14 25	10	24	20.75	15	28	5.7%	-6 50 [-13 35 0 35]	
Subtotal (95% CI)	14.20	10	259	20.75	15	255	28.9%	-0.98 [-3.00, 1.03]	-
Heterogeneity: $Tau^2 = 1$	1 70 [.] Chi	$^{2} = 6.00$	df = 4	$(P = 0)^{1}$	20)· I ² =	33%	2010 / 0	0.00 [0.00, 0.00]	-
Test for everall offect:	7 = 0.96	P = 0.00, P = 0.3	,ui – – 1)	(i = 0	20), 1 =	0070			
	0.30	,i = 0.5	-,						
rest for overall effect. 2						633	100.0%	-2.35 [-6.52, 1.82]	
Total (95% CI)			626						
Total (95% CI) Heterogeneity: Tau ² = 6	66.73; Cł	าi² = 105	626 58.32, d	df = 16 (P < 0.0	0001);	l² = 98%		
Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: 2	6.73; Cl Z = 1.10	าi² = 105 (P = 0.2)	626 58.32, d 7)	df = 16 (P < 0.0	0001);	l² = 98%		
Total (95% CI) Heterogeneity: Tau ² = (Test for overall effect: 2 Test for subaroup diffe	66.73; Cł Z = 1.10 rences: C	ni² = 105 (P = 0.23)hi² = 0.3	626 58.32, d 7) 37. df =	df = 16 (= 1 (P =	P < 0.0	0001); ² = 0%	l² = 98%		-10 -5 0 5 10 Favours Intervention Favours Control
Total (95% CI) Heterogeneity: Tau ² = (Test for overall effect: 2 Test for suboroup differ	66.73; Cl Z = 1.10 rences: C	ni² = 105 (P = 0.2))hi² = 0.3	626 58.32, c 7) 37. df =	df = 16 (= 1 (P =	P < 0.0	0001); ² = 0%	l² = 98%		-10 -5 0 5 10 Favours Intervention Favours Control

	Inte	erventio	n	c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
3.1.1 NMES									
Baron2022[12]	6.6	7.6	76	8.4	7.7	73	9.4%	-1.80 [-4.26, 0.66]	
Campos2022[18]	12	5.19	34	15	10.37	40	5.3%	-3.00 [-6.66, 0.66]	
Cerqueira 2018[19]	2.57	0.53	26	2.66	0.51	33	25.7%	-0.09 [-0.36, 0.18]	•
Chen2019[3]	8.34	2.36	27	10.45	2.62	29	17.5%	-2.11 [-3.41, -0.81]	-
Dall' Acqua2017[21]	10	4	11	16	9	14	2.8%	-6.00 [-11.27, -0.73]	
Kho2015[16]	22	17	16	20	17	18	0.7%	2.00 [-9.45, 13.45]	
Liu2023[24]	17.85	10.27	40	19.3	14.96	40	2.5%	-1.45 [-7.07, 4.17]	
Mahran2023[25]	6.3	2	60	19.6	1.6	58		Not estimable	
Othman2023[28]	21.1	5	30	21.5	4.42	30	9.8%	-0.40 [-2.79, 1.99]	
Patsaki2017[29]	14	14	63	15	18	65	2.6%	-1.00 [-6.58, 4.58]	
Santos2020[31]	13.8	6.9	11	14.2	9.7	15	2.0%	-0.40 [-6.78, 5.98]	
Silva2019[32]	19	11.85	30	19.5	11.33	30	2.3%	-0.50 [-6.37, 5.37]	
Sumin2022[33]	8	4.44	18	7	1.48	19	11.0%	1.00 [-1.16, 3.16]	
Vieira2023[34]	16.5	11.7	20	16.1	12.7	20	1.5%	0.40 [-7.17, 7.97]	
Subtotal (95% CI)			402			426	93.1%	-0.91 [-1.83, 0.00]	•
Heterogeneity: Tau ² =	0.70; Cł	ni² = 19.	07, df =	= 12 (P =	= 0.09);	l ² = 379	6		
Test for overall effect:	Z = 1.96	(P = 0.	05)						
3.1.2 EMS									
Nakamura2019[27]	9.9	5.7	21	10.6	4.7	16	6.1%	-0.70 [-4.05, 2.65]	
Routsi2010[30]	23	15	24	34	22	28	0.8%	-11.00 [-21.12, -0.88]	
Subtotal (95% CI)			45			44	6.9%	-4.70 [-14.54, 5.14]	
Heterogeneity: Tau ² =	38.25; C	chi² = 3.	59. df =	= 1 (P =	0.06); l ^a	² = 72%			
Test for overall effect:	Z = 0.94	(P = 0.	35)						
Total (95% CI)			447			470	100.0%	-1.02 [-1.96, -0.08]	◆
Heterogeneity: Tau ² =	0.88; Cł	ni² = 23.	52. df =	= 14 (P =	= 0.05):	$ ^2 = 40^{\circ}$	6		
Test for overall effect:	Z = 2.12	(P = 0)	03)				-		-20 -10 0 10 20
Test for subaroup diffe	erences	$Chi^2 = 0$.56. df	= 1 (P =	= 0.45)	l² = 0%			Favours Intervention Favours Control
E 5									
st plot of ICU LOS.									

Li et al.

Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random. 95% CI IV. Random. 95% CI 4.1.1 NMES Campos2022[18] 22 18.51 34 31 20 40 7.3% -9.00 [-17.78, -0.22] Chen2019[3] 13.21 2.21 27 15.38 3.67 29 31.3% -2.17 [-3.74, -0.60] Kho2015[16] 36 22 16 35 20 18 3.2% 1.00 [-13.20, 15.20] Liu2023[24] 23.98 13.95 40 25.08 17.28 40 10.6% -1.10 [-7.98, 5.78] Silva2019[32] 34 19.41 30 42 26.67 30 4.5% -8.00 [-19.80, 3.80] Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% 3.00 [0.09, 5.91] Viera2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% CI) 185 196 84.7% -1.44 [-4.71, 1.83] -4.12 EMS ChenA 2019[20] 25<	
4.1.1 NMES Campos2022[18] 22 18.51 34 31 20 40 7.3% -9.00 [-17.78, -0.22] Chen2019[3] 13.21 2.21 27 15.38 3.67 29 31.3% -2.17 [-3.74, -0.60] Kho2015[16] 36 22 16 35 20 18 3.2% 1.00 [-13.20, 15.20] Liu2023[24] 23.98 13.95 40 25.08 17.28 40 10.6% -1.10 [-7.98, 5.78] Silva2019[32] 34 19.41 30 42 26.67 30 4.5% -8.00 [-19.80, 3.80] Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% 3.00 [0.09, 5.91] Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% CI) 185 196 84.7% -1.44 [-4.71, 1.83] -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44 -44	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Kho2015[16] 36 22 16 35 20 18 3.2% 1.00 [-13.20, 15.20] Liu2023[24] 23.98 13.95 40 25.08 17.28 40 10.6% -1.10 [-7.98, 5.78] Silva2019[32] 34 19.41 30 42 26.67 30 4.5% -8.00 [-19.80, 3.80] Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% 3.00 [0.09, 5.91] Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% CI) 185 196 84.7% -1.44 [-4.71, 1.83] Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% -1.44 [-4.71, 1.84] Test for overall effect: Z = 0.87 (P = 0.39) -3.20 [-9.28, 2.88] -3.20 [-9.28, 2.88] Subtotal (95% CI) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% -1.45 [-4.12, 1.23] -1.45 [-4.12, 1.23]	
Liu2023[24] 23.98 13.95 40 25.08 17.28 40 10.6% -1.10 [-7.98, 5.78] Silva2019[32] 34 19.41 30 42 26.67 30 4.5% -8.00 [-19.80, 3.80] Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% 3.00 [0.09, 5.91] Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% Cl) 185 196 84.7% -1.44 [-4.71, 1.83] Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% Test for overall effect: Z = 0.87 (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Silva2019[32] 34 19.41 30 42 26.67 30 4.5% -8.00 [-19.80, 3.80] Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% $3.00 [0.09, 5.91]$ Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% CI) 185 196 84.7% -1.44 [-4.71, 1.83] Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% Test for overall effect: Z = 0.87 (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% CI) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% CI) 222 229 100.0% -1.45 [-4.12, 1.23]	
Sumin2022[33] 25 5.18 18 22 3.7 19 24.8% $3.00 [0.09, 5.91]$ Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% $-1.20 [-15.94, 13.54]$ Subtotal (95% CI) 185 196 84.7% $-1.44 [-4.71, 1.83]$ Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% rest for overall effect: Z = 0.87 (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% $-3.20 [-9.28, 2.88]$ Subtotal (95% CI) 37 33 15.3% $-2.62 [-8.26, 3.02]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% rest for overall effect: Z = 0.91 (P = 0.36) Total (95% CI) 222 229 100.0% $-1.45 [-4.12, 1.23]$	
Vieira2023[34] 25.5 22.4 20 26.7 25.1 20 3.0% -1.20 [-15.94, 13.54] Subtotal (95% Cl) 185 196 84.7% -1.44 [-4.71, 1.83] Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% Test for overall effect: Z = 0.87 (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Subtotal (95% Cl) 185 196 84.7% -1.44 [- 4.71 , 1.83] Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% Test for overall effect: Z = 0.87 (P = 0.39) $4.1.2$ EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Heterogeneity: Tau ² = 7.78; Chi ² = 13.83, df = 6 (P = 0.03); l ² = 57% Test for overall effect: Z = 0.87 (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Test for overall effect: $Z = 0.87$ (P = 0.39) 4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% CI) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% CI) 222 229 100.0% -1.45 [-4.12, 1.23]	
4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% CI) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% CI) 222 229 100.0% -1.45 [-4.12, 1.23]	
4.1.2 EMS ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% CI) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36)	
ChenA 2019[20] 25 22.96 16 24 21.48 17 2.8% 1.00 [-14.19, 16.19] Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 [-9.28, 2.88] Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Nakamura2019[27] 17.4 9.9 21 20.6 8.9 16 12.5% -3.20 $[-9.28, 2.88]$ Subtotal (95% Cl) 37 33 15.3% -2.62 $[-8.26, 3.02]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 $[-4.12, 1.23]$	
Subtotal (95% Cl) 37 33 15.3% -2.62 [-8.26, 3.02] Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% -2.62 [-8.26, 3.02] Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Heterogeneity: Tau ² = 0.00; Chi ² = 0.25, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 0.91 (P = 0.36) Total (95% CI) 222 229 100.0% -1.45 [-4.12, 1.23]	
Test for overall effect: Z = 0.91 (P = 0.36) Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Total (95% CI) 222 229 100.0% -1.45 [-4.12, 1.23]	
Total (95% Cl) 222 229 100.0% -1.45 [-4.12, 1.23]	
Heterogeneity: $1au^2 = 5.31$; $Chl^2 = 14.29$, $df = 8$ (P = 0.07); $l^2 = 44\%$	+
Test for overall effect: Z = 1.06 (P = 0.29)	trol
Test for subaroup differences: Chi ² = 0.13. df = 1 (P = 0.72). I ² = 0%	101
URE 6	
est plot of hospital LOS.	

Phudu on Pubano	Inte	rventio	n Tetal	Maar	Control	Tatal	Walakt	Mean Difference	Mean Difference
Study or Subgroup	wean	50	lotal	mean	50	Iotai	weight	IV, Random, 95% CI	IV, Random, 95% CI
5.1.1 NMES					10 50		7	0.50.00.00.000	
Campos2022[18]	58.5	3.7	18	50	12.59	22	7.6%	8.50 [2.97, 14.03]	
Cerqueira 2018[19]	57.24	4.54	26	57.24	4.52	33	10.3%	0.00 [-2.33, 2.33]	
Chen2019[3]	55.97	8.43	27	46.32	7.36	29	8.8%	9.65 [5.49, 13.81]	
Kho2015[16]	53	4	16	50	7	18	9.2%	3.00 [-0.78, 6.78]	
_iu2023[24]	52.2	11.7	40	44.1	15.7	40	7.1%	8.10 [2.03, 14.17]	
Othman2023[28]	49.77	2.19	30	41.1	3.84	30	10.8%	8.67 [7.09, 10.25]	
Patsaki2017[29]	50	13	63	51	10	65	8.9%	-1.00 [-5.03, 3.03]	
Subtotal (95% CI)			220			237	62.7%	5.12 [1.36, 8.87]	
Heterogeneity: Tau ² = 2	21.46; Ch	ni² = 54.	17, df =	= 6 (P <	0.0000	1); l² =	89%		
Test for overall effect: Z	: = 2.67 (P = 0.0	08)						
5.1.2 EMS									
Abu-Khaber 2013[15]	20.6	5.68	40	21	9.76	40	9.4%	-0.40 [-3.90, 3.10]	
Fossat 2018[22]	45.33	22.44	158	48.66	15.71	154	8.7%	-3.33 [-7.62, 0.96]	
Routsi2010[30]	56.72	2.25	24	52	4.5	28	10.6%	4.72 [2.83, 6.61]	
Subtotal (95% CI)			222			222	28.7%	0.61 [-4.38, 5.59]	
Heterogeneity: Tau ² = 1	6.54: Ch	ni² = 14.9	97. df =	= 2 (P =	0.0006): l ² = 8	7%	• / •	
Test for overall effect: Z	:= 0.24 (P = 0.8	1)	- (-	,	,,			
5.1.3 FES									
Waldauf2020[35]	42.4	10.6	42	39.4	10.2	46	8.6%	3.00 [-1.35, 7.35]	
Subtotal (95% CI)			42			46	8.6%	3.00 [-1.35, 7.35]	
Heterogeneity: Not app	licable								
Test for overall effect: Z	: = 1.35 (P = 0.1	B)						
Total (95% CI)			484			505	100.0%	3.62 [0.94, 6.30]	•
Heterogeneity: $Tau^2 = 1$	6.73: Ch	ni² = 78 a	89. df =	= 10 (P	< 0.000	01): l ² =	87%		
Test for overall effect: 7	' = 2.65 (P = 0.0	08)		0.000	.,,.	51 /0		-10 -5 0 5 10
Test for subgroup differ	ances C	$hi^2 = 2$	00) D4 df-	2 (P -	0.36) #	2 = 2 10	6		Favours Control Favours Intervention
	ences. C	- 2.0	54. ui -	- Z (F =	0.001.1	- 2.17	U		
RE 7									
st plot of MRC scores									
•									

significant heterogeneity, which is a significant limitation of our work. Future studies with larger samples and longer follow-ups are needed to comprehensively explore the short and long-term effects of electrical stimulation on patient outcomes to understand the intervention's effects further.

Conclusion

To conclude, the application of electrical stimulation in the ICU demonstrates a notable improve in MRC scores. In critical care, NMES is crucial for preventing muscle atrophy and improving recovery outcomes. By using NMES, muscles can be activated and maintained even when patients are unable to exercise actively. Nevertheless, given the constraints posed by the quality and sample size of the studies included, the broader impact should be substantiated through additional high-quality, large-scale, multicenter investigations.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

LL: Writing – review & editing, Writing – original draft, Supervision, Formal analysis, Conceptualization. FL: Writing – review & editing, Resources, Funding acquisition. XZ: Writing – original draft, Methodology, Investigation. YS: Writing – original draft, Software, Data curation. SL: Writing – original draft, Project

References

1. Geng Z, Zhang B. Electroacupuncture for intensive care unit acquired weakness: review and perspectives. *Acupunct Med.* (2021) 39:387–8. doi: 10.1177/0964528420938390

2. Zayed Y, Kheiri B, Barbarawi M, Chahine A, Rashdan L, Chintalapati S, et al. Effects of neuromuscular electrical stimulation in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. *Aust Crit Care.* (2020) 33:203–10. doi: 10.1016/j.aucc.2019.04.003

3. Chen YH, Hsiao HF, Li LF, Chen NH, Huang CC. Effects of electrical muscle stimulation in subjects undergoing prolonged mechanical ventilation. *Respir Care*. (2019) 64:262–71. doi: 10.4187/respcare.05921

4. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. (2015) 19:274. doi: 10.1186/s13054-015-0993-7

5. Tipping CJ, Harrold M, Holland A, Romero L, Nisbet T, Hodgson CL. The effects of active mobilization and rehabilitation in the ICU on mortality and function: a systematic review. *Intensive Care Med.* (2017) 43:171–83. doi: 10.1007/s00134-016-4612-0

6. Hodgson CL, Bailey M, Bellomo R, Berney S, Buhr H, Denehy L, et al. A binational multicenter pilot feasibility randomized controlled trial of early goal-directed mobilization in the ICU. *Crit Care Med.* (2016) 44:1145–52. doi: 10.1097/CCM.00000000001643

7. Trethewey SP, Brown N, Gao F, Turner AM. Interventions for the management and prevention of sarcopenia in the critically ill: a systematic review. *J Crit Care.* (2019) 50:287–95. doi: 10.1016/j.jcrc.2019.01.008

8. Cheng J, Kong J, Wang R, Ji K, Gao H, Yao L, et al. Meta-analysis of effects of neuromuscular electrical stimulation of lower limbs on patients with mechanical ventilation in the intensive care unit. *Chinese Crit Care Med.* (2021) 33:1243–8. doi: 10.3760/cma.j.cn121430-20210628-00962

9. Liu M, Luo J, Zhou J, Zhu X. Intervention effect of neuromuscular electrical stimulation on ICU acquired weakness: a meta-analysis. *Int J Nurs Sci.* (2020) 7:228–37. doi: 10.1016/j.ijnss.2020.03.002

10. Waldauf P, Jiroutková K, Krajčová A, Puthucheary Z, Duška F. Effects of rehabilitation interventions on clinical outcomes in critically ill patients: systematic review and meta-analysis of randomized controlled trials. *Crit Care Med.* (2020) 48:1055–65. doi: 10.1097/CCM.00000000004382

11. Anekwe DE, Biswas S, Bussières A, Spahija J. Early rehabilitation reduces the likelihood of developing ICU-acquired weakness: a systematic review and meta-analysis. *Physiotherapy*. (2020) 107:1–10. doi: 10.1016/j.physio.2019.12.004

12. Baron MV, Silva PE, Koepp J, Urbanetto JS, Santamaria AFM, dos Santos MP, et al. Efficacy and safety of neuromuscular electrical stimulation in the prevention of pressure injuries in critically ill patients: a randomized controlled trial. *Ann Intensive Care.* (2022) 12:53. doi: 10.1186/s13613-022-01029-1

administration, Methodology. HY: Writing – original draft, Supervision, Investigation.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev.* (2021) 10:89. doi: 10.1186/s13643-021-01626-4

14. JPT Higgins, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (2023) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available at: www.training.cochrane.org/handbook

15. Abu-Khaber HA, Abouelela AMZ, Abdelkarim EM. Effect of electrical muscle stimulation on prevention of ICU acquired muscle weakness and facilitating weaning from mechanical ventilation. *Alexandria J Med.* (2013) 49:309–15. doi: 10.1016/j. ajme.2013.03.011

16. Kho ME, Truong AD, Zanni JM, Brower RG, Palmer JB, Needham DM, et al. Neuromuscular electrical stimulation in mechanically ventilated patients: a shamcontrolled pilot trial with blinded outcome assessment. *J Crit Care*. (2015) 30:32–9. doi: 10.1016/j.jcrc.2014.09.014

17. Fischer A, Spiegl M, Altmann K, Winkler A, Salamon A, Themessl-Huber M, et al. Effects of neuromuscular electrical stimulation on muscle mass, strength, and functional outcomes in critically ill patients after cardiothoracic surgery: the Catastim 2 randomized controlled trial. *Crit Care.* (2016) 20:30. doi: 10.1186/s13054-016-1199-3

18. Campos DR, Bueno TBC, Anjos JSGG, Dantas BG, Gosselink R, Guirro RRJ, et al. Improving functional status and reducing hospitalization days in critically ill patients: early neuromuscular electrical stimulation in addition to early mobilization. *Crit Care Med.* (2022) 50:1116–26. doi: 10.1097/CCM.00000000005557

 Fontes Cerqueira TC, Cerqueira Neto ML, Cacau LAP, Oliveira GU, Silva Júnior WM, Carvalho VO, et al. Ambulation capacity and functional outcome in patients undergoing neuromuscular electrical stimulation after cardiac valve surgery. *Medicine* (*Baltimore*). (2018) 97:e13012. doi: 10.1097/MD.00000000003013012

20. Chen S, Jiang Y, Yu B, Mi Y, Tan Y, Yao J, et al. Preventing ICU-acquired weakness in chronic obstructive pulmonary disease patients with mechanical ventilation: the effect of transcutaneous neuromuscular electrical stimulation. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. (2019) 31:709–13. doi: 10.3760/cma.jissn.2095-4352.2019.06.010

21. Acqua A, Sachetti A, Santos LJ, Lemos F, Bianchi T, Naue W, et al. Preserving abdominal and chest muscle thickness in critically ill patients: a randomized clinical trial using neuromuscular electrical stimulation. *J Rehabil Med.* (2017) 49:40–8. doi: 10.2340/16501977-2168

22. Fossat G, Baudin F, Courtes L, Bobet S, Dupont A, Bretagnol A, et al. Enhancing global muscle strength in critically ill adults: a randomized clinical trial on in-bed leg cycling and quadriceps electrical stimulation. *JAMA*. (2018) 320:368–78. doi: 10.1001/jama.2018.9592

23. Gerovasili V, Stefanidis K, Vitzilaios K, Karatzanos E, Politis P, Koroneos A, et al. Preservation of muscle mass in critically ill patients: a randomized study on electrical muscle stimulation. *Crit Care*. (2009) 13:R161. doi: 10.1186/cc8123

24. Liu Y, Gong Y, Zhang C, Meng P, Gai Y, Han X, et al. Effect of neuromuscular electrical stimulation combined with early rehabilitation therapy on mechanically ventilated patients: a prospective randomized controlled study. *BMC Pulm Med.* (2023) 23:272. doi: 10.1186/s12890-023-02481-w

25. Mahran GSK, Mehany MM, Abbas MS, Shehata AER, AbdElhafeez AS, Obiedallah AA, et al. Short-term outcomes of neuromuscular electrical stimulation in critically ill patients. *Crit Care Nurs Q.* (2023) 46:126–35. doi: 10.1097/CNQ.00000000000445

26. McCaughey EJ, Jonkman AH, Boswell-Ruys CL, McBain RA, Bye EA, Hudson AL, et al. Assisting ventilator weaning in critical illness: a double-blinded, randomized pilot study on abdominal functional electrical stimulation. *Crit Care*. (2019) 23:261. doi: 10.1186/s13054-019-2544-0

27. Nakamura K, Kihata A, Naraba H, Kanda N, Takahashi Y, Sonoo T, et al. Reducing muscle volume loss in critically ill patients: efficacy of belt electrode skeletal muscle electrical stimulation – a randomized controlled trial. *J Rehabil Med.* (2019) 51:705–11. doi: 10.2340/16501977-2594

28. Othman SY, Elbiaa MA, Mansour ER, el-Menshawy AM, Elsayed SM. Effect of neuromuscular electrical stimulation and early physical activity on ICU-acquired weakness in mechanically ventilated patients: a randomized controlled trial. *Nurs Crit Care.* (2023) 29:584–96. doi: 10.1111/nicc.13010

29. Patsaki I, Gerovasili V, Sidiras G, Karatzanos E, Mitsiou G, Papadopoulos E, et al. Improving muscle strength in intensive care unit survivors: a randomized trial with neuromuscular stimulation and individualized rehabilitation. *J Crit Care.* (2017) 40:76–82. doi: 10.1016/j.jcrc.2017.03.014

30. Routsi C, Gerovasili V, Vasileiadis I, Karatzanos E, Pitsolis T, Tripodaki ES, et al. Preventing critical illness Polyneuromyopathy: a randomized parallel intervention trial with electrical muscle stimulation. *Crit Care*. (2010) 14:R74. doi: 10.1186/cc8987

31. dos Santos FV, Cipriano Jr G, Vieira L, Güntzel Chiappa AM, Cipriano GBF, Vieira P, et al. Neuromuscular electrical stimulation combined with exercise decreases duration of mechanical ventilation in ICU patients: a randomized controlled trial. *Physiother Theory Pract.* (2020) 36:580–8. doi: 10.1080/09593985.2018.1490363

32. Silva PE, de Cássia Marqueti R, Livino-de-Carvalho K, de Araujo AET, Castro J, da Silva VM, et al. Neuromuscular electrical stimulation in critically ill traumatic brain injury patients attenuates muscle atrophy, neurophysiological disorders, and weakness: a randomized controlled trial. *J Intensive Care*. (2019) 7:59. doi: 10.1186/s40560-019-0417-x

33. Sumin AN, Oleinik PA, Bezdenezhnykh AV, Ivanova AV. Early rehabilitation with neuromuscular electrical stimulation for patients with postoperative complications after cardiovascular surgery: a randomized controlled trial. *Medicine (Baltimore)*. (2020) 99:e22769. doi: 10.1097/MD.00000000022769

34. Vieira L, Silva P, de Melo PF, Maldaner V, Durigan JQ, Marqueti RC, et al. Early neuromuscular electrical stimulation preserves muscle size and quality and maintains systemic levels of signaling mediators of muscle growth and inflammation in patients with traumatic brain injury: a randomized clinical trial. *Crit Care Res Prac.* (2023) 2023:1–12. doi: 10.1155/2023/9335379

35. Waldauf P, Hrušková N, Blahutova B, Gojda J, Urban T, Krajčová A, et al. Progressive mobility program for mechanically ventilated patients: a randomized controlled trial with 6 months follow-up, using functional electrical stimulation-assisted cycle Ergometry. *Thorax.* (2021) 76:664–71. doi: 10.1136/thoraxjnl-2020-215755

36. Doucet BM, Lam A, Griffin L. Neuromuscular electrical stimulation for skeletal muscle function. *Yale J Biol Med.* (2012) 85:201–15.

37. Fujiwara T, Kawakami M, Honaga K, Tochikura M, Abe K. Hybrid assistive neuromuscular dynamic stimulation therapy: a new strategy for improving upper extremity function in patients with hemiparesis following stroke. *Neural Plast.* (2017) 2017;2350137:1–5. doi: 10.1155/2017/2350137

38. Angelopoulos E, Karatzanos E, Dimopoulos S, Mitsiou G, Stefanou C, Patsaki I, et al. Acute microcirculatory effects of medium frequency versus high frequency neuromuscular electrical stimulation in critically ill patients – a pilot study. *Ann Intensive Care.* (2013) 3:39. doi: 10.1186/2110-5820-3-39

39. Ojima M, Takegawa R, Hirose T, Ohnishi M, Shiozaki T, Shimazu T. Hemodynamic effects of electrical muscle stimulation in the prophylaxis of deep vein thrombosis for intensive care unit patients: a randomized trial. *J Intensive Care*. (2017) 5:9. doi: 10.1186/ s40560-016-0206-8

40. Gibson JN, Smith K, Rennie MJ. Preventing disuse muscle atrophy through electrical stimulation: sustaining protein synthesis. *Lancet.* (1988) 332:767–70. doi: 10.1016/s0140-6736(88)92417-8

41. Maffiuletti NA, Roig M, Karatzanos E, Nanas S. Systematic review: neuromuscular electrical stimulation for preventing skeletal muscle weakness and atrophy in critically ill patients. *BMC Med.* (2013) 11:137. doi: 10.1186/1741-7015-11-137

42. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. *JAMA*. (2013) 310:1591-600. doi: 10.1001/jama.2013.278481

43. Burke D, Gorman E, Stokes D, Lennon O. A systematic review and meta-analysis evaluating neuromuscular electrical stimulation in critical care using the ICF framework. *Clinical Respir J.* (2016) 10:407–20. doi: 10.1111/crj.12234

44. Scottish Renal Association. Medical and nursing abstract booklet of the Scottish renal Association for the Year 2020. *Scott Med J.* (2021) 66:NP1–NP14. doi: 10.1177/0036933021996831